Sutro Biopharma, Inc. (STRO) Reports Q3 Loss, Misses Revenue Estimates
Portfolio Pulse from
Sutro Biopharma, Inc. (STRO) reported a Q3 loss of $0.59 per share, which was better than the expected loss of $0.74 per share. However, the company missed revenue estimates.
November 14, 2024 | 12:00 am
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
Sutro Biopharma reported a Q3 loss of $0.59 per share, better than the expected $0.74 loss, but missed revenue estimates.
The better-than-expected EPS loss could be seen positively, but missing revenue estimates may offset this, leading to a neutral short-term impact on the stock price.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 100